Research programme: insulin resistance therapies - Pfizer/Sanford-Burnham Medical Research Institute

Drug Profile

Research programme: insulin resistance therapies - Pfizer/Sanford-Burnham Medical Research Institute

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer; Sanford-Burnham Medical Research Institute
  • Developer Pfizer; Sanford Burnham Prebys Medical Discovery Institute
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Insulin resistance

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Insulin-resistance in USA
  • 13 Aug 2013 Early research in Insulin resistance (in obesity and diabetes) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top